Today marks Metastatic Breast Cancer Awareness Day — a time to honor those living with stage IV breast cancer, remember those we’ve lost, and reaffirm our shared commitment to ending the disease.
While significant progress has been made in early-stage breast cancer treatment, metastatic breast cancer (MBC) — when cancer spreads beyond the breast to other organs — continues to present complex challenges. Among the most difficult of these is a rare but devastating complication called leptomeningeal metastases (LM).
What Are Leptomeningeal Metastases (LM)?
Leptomeningeal metastases occur when cancer cells travel to the membranes surrounding the brain and spinal cord. LM is most commonly found in patients with breast, lung, melanoma, or gastrointestinal cancers, and symptoms may include headaches, confusion, vision changes, or weakness.
Despite its severity, there are currently no FDA-approved treatments for LM, leaving patients and caregivers searching for better options. Learn more about LM and its impact on patients here.
The ReSPECT-LM Clinical Trial: A New Path Forward
At Plus Therapeutics, we’re working to change that. Our ongoing ReSPECT-LM clinical trial is designed to evaluate REYOBIQ™ (rhenium-186 nanoliposomes) — an innovative, targeted radiotherapeutic that delivers radiation directly to cancer cells within the cerebrospinal fluid (CSF).
Unlike traditional systemic therapies, this approach allows for precise, localized treatment of LM, with the goal of improving outcomes while minimizing side effects.
Learn more or find a participating site: www.respect-trials.com
If you or someone you know has been diagnosed with leptomeningeal metastases secondary to breast cancer, you may be eligible to participate in this study. Visit the ReSPECT-Trials.com eligibility page to learn more and submit an inquiry.
Awareness. Advocacy. Action.
Days like Metastatic Breast Cancer Awareness Day remind us that awareness alone is not enough — progress depends on research, collaboration, and patient participation. Together with organizations like the Cancer Prevention and Research Institute of Texas (CPRIT) and advocacy partners across the country, we’re working to illuminate new possibilities for patients facing the most challenging forms of metastatic disease.
Learn more about ongoing studies and future research opportunities at www.respect-trials.com.
Recent Comments